At NIMML we investigate the role of gastric macrophages in the outcome of infection and the role of NLRX1 in sensing and orchestrating the mucosal immune response
We are interested in genes with immunoregulatory functions that can be used for developing new therapeutics
NIMML has more than 20 years of experience in developing pig models of infectious and immune-mediated disease like colitis, influenza or Helicobacter pylori infection.
With our mouse model of CDAD we are studying the interplay between the normal colon microbiome, C. difficile and the balance between effector and regulatorymucosal responses.
NIMML employs mouse models of obesity, hyperglycemia and insulin resistance to investigate promising therapeutic targets and compounds for diabetes mellitus.
We are working in developing host-based therapeutic approaches that alone or in combination with antivirals can be used to decrease morbidity and mortality during episodes of seasonal or pandemic flu